RECRUITING

Role of Mitochondrial Bioenergetics in Resilience for Gynecologic Cancer

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research study is to see if patients with endometrial and ovarian cancer are willing to complete physical and cognitive assessments before treatment and again after treatment has ended.

Official Title

The Role of Mitochondrial Bioenergetics in Resilience in Older Adults With Gynecologic Cancer Receiving Cancer Reductive Treatment

Quick Facts

Study Start:2025-11
Study Completion:2027-04
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07046936

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Ability to understand and willingness to sign an IRB-approved informed consent
  2. * Age ≥50 years at the time of enrollment
  3. * Newly diagnosed or suspected FIGO Stage II-IV ovarian/primary peritoneal/fallopian tube carcinoma of any histological subtype OR FIGO Stage II-IV endometrial carcinoma of any histological subtype
  4. * Planned, standard of care treatment consisting of neoadjuvant chemotherapy, tumor reduction surgery, and adjuvant chemotherapy
  5. * Ability to read and understand the English language
  1. * Previously treated for ovarian or endometrial cancer
  2. * History of brain metastases, whole brain irradiation, poorly controlled psychiatric disorders defined by hospitalization within the last 3 months for psychiatric diagnoses, traumatic brain injury, cerebrovascular event, or dementia
  3. * Currently taking anti-amyloid agents, cholinesterase inhibitors, or glutamate regulator
  4. * Documented physical or psychological comorbidity that would limit participant's ability to understand or comply with study procedures for the entire length of the study

Contacts and Locations

Study Contact

Brandy Baker
CONTACT
(336) 713-8941
brandy.baker@advocatehealth.org

Principal Investigator

Bumsoo Ahn, PhD
PRINCIPAL_INVESTIGATOR
Wake Forest University Health Sciences

Study Locations (Sites)

Atrium Health Levine Cancer
Charlotte, North Carolina, 28204
United States
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157
United States

Collaborators and Investigators

Sponsor: Wake Forest University Health Sciences

  • Bumsoo Ahn, PhD, PRINCIPAL_INVESTIGATOR, Wake Forest University Health Sciences

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-11
Study Completion Date2027-04

Study Record Updates

Study Start Date2025-11
Study Completion Date2027-04

Terms related to this study

Keywords Provided by Researchers

  • Mitochondrial Bioenergetics
  • Cancer

Additional Relevant MeSH Terms

  • Gynecologycal Cancer